- Home
- CSAN vs SUPN Comparison
CSAN vs SUPN Comparison
Compare CSAN & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSAN
- SUPN
- Stock Information
- Founded
- CSAN 1936
- SUPN 2005
- Country
- CSAN Brazil
- SUPN United States
- Employees
- CSAN N/A
- SUPN N/A
- Industry
- CSAN Retail-Auto Dealers and Gas Stations
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- CSAN Consumer Discretionary
- SUPN Health Care
- Exchange
- CSAN Nasdaq
- SUPN Nasdaq
- Market Cap
- CSAN 2.3B
- SUPN 2.1B
- IPO Year
- CSAN N/A
- SUPN 2012
- Fundamental
- Price
- CSAN $5.13
- SUPN $33.05
- Analyst Decision
- CSAN Strong Buy
- SUPN Hold
- Analyst Count
- CSAN 1
- SUPN 2
- Target Price
- CSAN $19.00
- SUPN $36.00
- AVG Volume (30 Days)
- CSAN 1.2M
- SUPN 495.6K
- Earning Date
- CSAN 02-26-2025
- SUPN 02-25-2025
- Dividend Yield
- CSAN 6.75%
- SUPN N/A
- EPS Growth
- CSAN N/A
- SUPN 130.79
- EPS
- CSAN 0.22
- SUPN 1.07
- Revenue
- CSAN $7,655,547,290.00
- SUPN $651,972,000.00
- Revenue This Year
- CSAN $330.06
- SUPN $7.94
- Revenue Next Year
- CSAN $2.09
- SUPN N/A
- P/E Ratio
- CSAN $5.80
- SUPN $30.90
- Revenue Growth
- CSAN 3.43
- SUPN 6.79
- 52 Week Low
- CSAN $4.95
- SUPN $25.53
- 52 Week High
- CSAN $14.81
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- CSAN 44.38
- SUPN 32.98
- Support Level
- CSAN $5.24
- SUPN $32.53
- Resistance Level
- CSAN $5.64
- SUPN $39.99
- Average True Range (ATR)
- CSAN 0.17
- SUPN 1.31
- MACD
- CSAN 0.02
- SUPN -0.69
- Stochastic Oscillator
- CSAN 26.28
- SUPN 6.71
About CSAN Cosan S.A. ADS
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.